Robert M. Califf, MD

The Anticoagulant Therapy with Bivalirudin to Assist in the <br />
Performance of Percutaneous Coronary Intervention in Patients with

08/01/2008

Mark A. Turco , MD, FACC;

Yoseph Shalev , MD;

Peter Ver Lee , MD;

A. Ralph Rodriguez , MD;

E. Magnus Ohman , MD;

Robert A. Harrington , MD;

Robert M. Califf , MD;

Jay H. Traverse , MD;

Kenneth W. Mahaffey , MD;

Bruce E. Lewis , MD;

Nancy M. Wildermann , BA;

Scott D. Berkowitz , MD;

Renee M. Oliverio , RN;

Heparin-induced thrombocytopenia (HIT) is infrequent and often goes unrecognized. It occurs in ~1% to 5% of the patients given unfractionated heparin,1 about 25–50% of whom will develop HIT with thrombotic syndrome (HITTS).2 Morbidity and...

Heparin-induced thrombocytopenia...

08/01/2008

Journal of Invasive Cardiology

Excerpts from: Consistency of Financial Interest Disclosures in the Biomedical Literature: The Case of Coronary Stents

06/04/2009

Robert M. Califf , MD;

Kevin P. Weinfurt ;

Damon M. Seils ;

Li Lin ;

Kevin A. Schulman ;

Janice P. Tzeng ;

Introduction The influence of commercial interests on medical science is an area of ongoing concern. Recent work has examined the extent of this influence1-5 and explored best practices for managing conflicts of interest.6-9 A particular...

Introduction The influence of...

06/04/2009

Cath Lab Digest